NCT05949424 - OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2024

Primary Completion Date

March 31, 2025

Study Completion Date

March 31, 2025

Conditions

Renal Cell CarcinomaOvarian CarcinomaThyroid CarcinomaBreast CarcinomaEndometrium Carcinoma

Interventions

DRUG

Olaparib

Starting dose of 200mg 2dd.

DRUG

Lenvatinib

Starting dose of 10mg 1dd.

DRUG

Sunitinib

Starting dose of 25mg 1dd 28/42 days.

DRUG

Palbociclib

Starting dose of 75mg 1dd 21/28 days.

DRUG

Pazopanib

Starting dose of 200mg 1dd.

DRUG

Olaparib

Starting dose of 300mg 2dd.

DRUG

Lenvatinib

Starting dose of 20mg 1dd for RCC or endometrial carcinoma, starting dose of 24mg 1dd for thyroid carcinoma.

DRUG

Sunitinib

Starting dose of 50mg 1dd 28/42 days.

DRUG

Palbociclib

Starting dose of 125mg 1dd 21/28 days.

DRUG

Pazopanib

Starting dose of 800mg 1dd.

Trial Locations (1)

9713 GZ

University Medical Center Groningen, Groningen

All Listed Sponsors

lead

University Medical Center Groningen

OTHER